Literature DB >> 21702734

Uncovering amyotrophic lateral sclerosis phenotypes: clinical features and long-term follow-up of upper motor neuron-dominant ALS.

Mario Sabatelli1, Marcella Zollino, Marco Luigetti, Alessandra Del Grande, Serena Lattante, Giuseppe Marangi, Mauro Lo Monaco, Francesca Madia, Emiliana Meleo, Giulia Bisogni, Amelia Conte.   

Abstract

The aim of our study was to analyse the natural history and clinical features of upper motor neuron- dominant (UMN-D) ALS. We studied a large series of sporadic ALS patients admitted in a single referral centre over a 23-year period. UMN-D phenotype was compared with other ALS forms, including classic ALS, flail arm and progressive muscular atrophy. Seven hundred and thirty-four sporadic ALS patients were included of which 163 had UMN-D ALS. The mean age of onset in UMN-D ALS (52 years) was 10 years lower than in classic ALS (61.4 years, p < 0.0001); sex ratio by age groups significantly differed with respect to other phenotypes. The pattern of spread of lower motor neuron signs in UMN-D was characterized by early involvement of upper limb muscles and late impairment of respiratory muscles. Duration of the disease was longer in the UMN-D group (56 months) than in classic ALS (33 months, p < 0.001). The UMN-D phenotype was a strong independent predictor of long survival. In summary, UMN-D ALS showed significant differences in age of onset, sex ratio, pattern of spreading and prognosis with respect to other ALS forms, most probably reflecting biological differences.

Entities:  

Mesh:

Year:  2011        PMID: 21702734     DOI: 10.3109/17482968.2011.580849

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler        ISSN: 1471-180X


  11 in total

1.  Evolution of the neurochemical profiles in the G93A-SOD1 mouse model of amyotrophic lateral sclerosis.

Authors:  Hongxia Lei; Elisabeth Dirren; Carole Poitry-Yamate; Bernard L Schneider; Rolf Gruetter; Patrick Aebischer
Journal:  J Cereb Blood Flow Metab       Date:  2018-02-05       Impact factor: 6.200

Review 2.  Prognostic factors for the course of functional status of patients with ALS: a systematic review.

Authors:  Huub Creemers; Hepke Grupstra; Frans Nollet; Leonard H van den Berg; Anita Beelen
Journal:  J Neurol       Date:  2014-11-11       Impact factor: 4.849

Review 3.  Challenges in the Understanding and Treatment of Amyotrophic Lateral Sclerosis/Motor Neuron Disease.

Authors:  Jeffrey Rosenfeld; Michael J Strong
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

4.  Factors predicting survival in ALS: a multicenter Italian study.

Authors:  Andrea Calvo; Cristina Moglia; Christian Lunetta; Kalliopi Marinou; Nicola Ticozzi; Gianluca Drago Ferrante; Carlo Scialo; Gianni Sorarù; Francesca Trojsi; Amelia Conte; Yuri M Falzone; Rosanna Tortelli; Massimo Russo; Adriano Chiò; Valeria Ada Sansone; Gabriele Mora; Vincenzo Silani; Paolo Volanti; Claudia Caponnetto; Giorgia Querin; Maria Rosaria Monsurrò; Mario Sabatelli; Nilo Riva; Giancarlo Logroscino; Sonia Messina; Nicola Fini; Jessica Mandrioli
Journal:  J Neurol       Date:  2016-10-24       Impact factor: 4.849

5.  Sural nerve pathology in ALS patients: a single-centre experience.

Authors:  Marco Luigetti; Amelia Conte; Alessandra Del Grande; Giulia Bisogni; Angela Romano; Mario Sabatelli
Journal:  Neurol Sci       Date:  2011-12-28       Impact factor: 3.307

Review 6.  Controversies and priorities in amyotrophic lateral sclerosis.

Authors:  Martin R Turner; Orla Hardiman; Michael Benatar; Benjamin R Brooks; Adriano Chio; Mamede de Carvalho; Paul G Ince; Cindy Lin; Robert G Miller; Hiroshi Mitsumoto; Garth Nicholson; John Ravits; Pamela J Shaw; Michael Swash; Kevin Talbot; Bryan J Traynor; Leonard H Van den Berg; Jan H Veldink; Steve Vucic; Matthew C Kiernan
Journal:  Lancet Neurol       Date:  2013-03       Impact factor: 44.182

7.  Unbiased Label-Free Quantitative Proteomics of Cells Expressing Amyotrophic Lateral Sclerosis (ALS) Mutations in CCNF Reveals Activation of the Apoptosis Pathway: A Workflow to Screen Pathogenic Gene Mutations.

Authors:  Flora Cheng; Alana De Luca; Alison L Hogan; Stephanie L Rayner; Jennilee M Davidson; Maxinne Watchon; Claire H Stevens; Sonia Sanz Muñoz; Lezanne Ooi; Justin J Yerbury; Emily K Don; Jennifer A Fifita; Maria D Villalva; Hannah Suddull; Tyler R Chapman; Thomas J Hedl; Adam K Walker; Shu Yang; Marco Morsch; Bingyang Shi; Ian P Blair; Angela S Laird; Roger S Chung; Albert Lee
Journal:  Front Mol Neurosci       Date:  2021-04-27       Impact factor: 5.639

8.  Genetic analysis in Chinese patients with familial or young-onset amyotrophic lateral sclerosis.

Authors:  Jing Ma; Xiaomin Pang; Shan Huang; Jing Zhang; Juan Wang; Rongjuan Zhao; Xueli Chang; Junhong Guo; Wei Zhang
Journal:  Neurol Sci       Date:  2021-09-26       Impact factor: 3.830

Review 9.  Quantifying disease progression in amyotrophic lateral sclerosis.

Authors:  Neil G Simon; Martin R Turner; Steve Vucic; Ammar Al-Chalabi; Jeremy Shefner; Catherine Lomen-Hoerth; Matthew C Kiernan
Journal:  Ann Neurol       Date:  2014-09-30       Impact factor: 10.422

10.  Changes in the concentrations of trimethylamine N-oxide (TMAO) and its precursors in patients with amyotrophic lateral sclerosis.

Authors:  Lu Chen; Yong Chen; Mingming Zhao; Lemin Zheng; Dongsheng Fan
Journal:  Sci Rep       Date:  2020-09-16       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.